Breast Cancer Clinical Trial
Official title:
Phase II Evaluation of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
Background:
- Mithramycin is a drug that was first tested as a cancer therapy in the 1960s. It acted
against some forms of cancer, but was never accepted as a treatment. Research suggests that
it may be useful against some cancers of the chest, such as lung and esophageal cancer or
mesothelioma. Researchers want to see if mithramycin can be used to treat these types of
cancer.
Objectives:
- To see if mithramycin is safe and effective against different chest cancers.
Eligibility:
- Individuals at least 18 years of age who have lung, esophagus, pleura, or mediastinum
cancers.
Design:
- Participants will be screened with a physical exam and medical history. Blood and urine
samples will be collected. Imaging studies and tumor tissue samples will be used to
monitor the cancer before treatment.
- Participants will receive mithramycin every day for 7 days, followed by 7 days without
treatment. Each 14-day round of treatment is called a cycle.
- Treatment will be monitored with frequent blood tests and imaging studies.
- Participants will continue to take the drug for as long as the side effects are not
severe and the tumor responds to treatment.
Background:
Increasing evidence indicates that activation of stem cell gene expression is a common
mechanism by which environmental carcinogens mediate initiation and progression of thoracic
malignancies. Similar mechanisms appear to contribute to extra-thoracic malignancies that
metastasize to the chest. Utilization of pharmacologic agents, which target gene regulatory
networks mediating stemness may be novel strategies for treatment of these neoplasms. Recent
studies performed in the Thoracic Epigenetics Laboratory, Thoracic and Oncology Surgery
Branch (TOSB)/National Cancer Institute (NCI), demonstrate that under exposure conditions
potentially achievable in clinical settings, mithramycin diminishes stem cell gene expression
and markedly inhibits growth of lung and esophageal cancer and malignant pleural mesothelioma
(MPM) cells in vitro and in vivo. These finding add to other recent preclinical studies
demonstrating impressive anti-tumor activity of mithramycin in epithelial malignancies and
sarcomas that frequently metastasize to the thorax.
Primary Objective:
-To assess clinical response rates of mithramycin administered as 6 hour intravenous
infusions in patients with malignancies involving lungs, esophagus, pleura, or mediastinum.
Eligibility:
- Patients with measurable inoperable, histologically confirmed primary lung and
esophageal carcinomas, thymic neoplasms, germ cell tumors, malignant pleural
mesotheliomas or chest wall sarcomas, as well as patients with gastric, colorectal or
renal cancers and sarcomas metastatic to the thorax are eligible.
- Patients with germline single nucleotide polymorphisms (SNPs) in adenosine
5-triphosphate binding cassette subfamily B member 4 (ABCB4), adenosine 5-triphosphate
binding cassette subfamily B member 11 (ABCB11), retinal-binding protein (RALBP) or
cytochrome P851 (CYP851) that are associated with resistance to mithramycin-induced
hepatotoxicity.
- Patients must have had or refused first-line standard therapy for their malignancies.
- Patients must be 18 years or older with an Eastern Cooperative Oncology Group (ECOG)
performance status of 0-2, without evidence of unstable or decompensated myocardial
disease. Patients must have adequate pulmonary reserve evidenced by forced expiratory
volume 1 (FEV1) and diffusing capacity for carbon monoxide (DLCO) equal to or greater
than 30% predicted; oxygen saturation greater than or equal to 92% on room air. Arterial
Blood Gas (ABG) will be drawn if clinically indicated.
- Patients must have a platelet count greater than 100,000, an absolute neutrophil count
(ANC) equal to or greater than 1500 without transfusion or cytokine support, a normal
prothrombin time (PT)/partial thromboplastin time (PTT), and adequate hepatic function
as evidenced by a total bilirubin of <1.5 times upper limits of normal (ULN) and
aspartate aminotransferase (AST)/alanine aminotransferase (ALT) less than or equal to 3
x ULN. Serum creatinine less than 3 or equal to 1.6 mg/ml, or creatinine clearance
greater than 70 ml/min/1.73m^2.
Design:
- Simon Optimal Two Stage Design for Phase II Clinical Trials targeting an objective
response rate (Response Evaluation Criteria in Solid Tumors (RECIST)) of 30%.
- Patients will be stratified based on location of primary disease (thoracic vs.
extra-thoracic).
- Patients will receive 6 hour infusions of mithramycin at 30 -50 mcg/kg every day for 7
days, every 21 days (1 cycle). Three cycles will constitute one course of therapy. Those
patients tolerating 30 mcg/kg infusions during the first cycle will receive subsequent
cycles of mithramycin at a dose of 50 mcg/kg using the same infusion schedule.
- Following each course of therapy, patients will undergo restaging studies. Patients
exhibiting objective response to therapy or stable disease by RECIST criteria will be
offered an additional course of therapy.
- Patients exhibiting disease progression will be removed from study.
- Biopsies of index lesions will be obtained at baseline and on day 8 of the second cycle
of therapy for analysis of molecular end-points.
- Pharmacokinetics will be assessed during cycle 1 and cycle 2 of the first course of
therapy.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |